Associated with decreased rectal cancer risk overall (OR = 0.65; 95% CI: 0.45–0.92) and specifically with rectal tumors bearing a TP53 mutation (OR = 0.60; 95% CI: 0.37–0.98). The gene discussed is TP53; the disease is rectal neoplasm.